Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_curated type ECO_0000205 NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- source_evidence_curated label "DisGeNET evidence - CURATED" NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- source_evidence_curated comment "Gene-disease associations manually curated." NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- ctd_human-20150221 importedOn "2015-02-21" NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion wasGeneratedBy ECO_0000218 NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion wasDerivedFrom ctd_human-20150221 NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion SIO_000772 15248218 NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion evidence source_evidence_curated NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.